Challenges of Driving CD30-directed CAR-T Cells to the Clinic

BMC Cancer - United Kingdom
doi 10.1186/s12885-019-5415-9
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Cd30-Chimeric Antigen Receptor (Car) T Cells for Therapy of Hodgkin Lymphoma (Hl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Automated Manufacturing of Potent CD20-directed CAR T Cells for Clinical Use

Human Gene Therapy
Molecular MedicineGeneticsMolecular Biology
2017English

Engineering CAR-T Cells

Biomarker Research
BiochemistryMolecular MedicineClinical Biochemistry
2017English

Clinical Trials of Dual-Target CAR T Cells, Donor-Derived CAR T Cells, and Universal CAR T Cells for Acute Lymphoid Leukemia

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2019English

BCMA CAR T Cells: The Winding Path to Success

Journal of Clinical Investigation
Medicine
2019English

Anti-Car-Engineered T Cells for Epitope-Based Elimination of Autologous CAR T Cells

Cancer Immunology, Immunotherapy
Cancer ResearchMedicineOncologyAllergyImmunology
2019English

Tracing the Path of CAR T Cells

Cancer Discovery
Oncology
2017English

CD30-CD30 Ligand Interaction in Primary Cutaneous CD30+T-Cell Lymphomas: A Clue to the Pathophysiology of Clinical Regression

Blood
BiochemistryImmunologyCell BiologyHematology
1999English

Chronic CD30-signaling in B Cells Results in Lymphomagenesis by Driving the Expansion of Plasmablasts and B1 Cells

Blood
BiochemistryImmunologyCell BiologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy